British semiconductor company MintNeuro has raised €4.4 million ($5 million) in new funding. The company develops specialised chips for neural devices, including brain implants and wearable technologies.
The new funding will help MintNeuro bring its products to market faster, deliver more pre-release chips to its partners, and expand its business internationally.
The funding round was led by Odyssey Ventures, with participation from 33East, JSK Investments, and Alumni Ventures. Existing investors, including Empirical Ventures, Jumpspace Ventures, and other early backers, also joined the round.
Michelle Robson, Founding Partner at Odyssey Ventures, adds: “Neural devices such as BCIs represent one of the most exciting frontier technology opportunities today, and significant value will accrue to those solving the foundational infrastructure challenges that stand between innovation and widespread adoption.
“MintNeuro has the technology, market pull and ambition to become a globally important semiconductor company, and we are backing this exceptional team as it scales from the UK into global markets, including Silicon Valley.”
Yiannis Eftychiou, co-founder and Partner at 33East, says: “What stood out to us is the sheer breadth of the hardware opportunity. MintNeuro is solving critical needs for neural implants today, with technology that can extend into wearables and beyond.”
Johnathan Matlock, co-founder and General Partner at Empirical Ventures, says: “We invested before the chips were in hand, and we are reinvesting now that MintNeuro has working silicon, deep customer traction and a clear path to becoming a category-defining semiconductor business.”
Commenting on the investment, Dorian Haci, co-founder and CEO of MintNeuro, says: “Every neural device depends on the chips inside it. Today, most device and therapy developers still have to choose between generic components that were never designed for the body and years of custom chip development.
“We are building the chips that end that trade-off. This funding moves us from technology validation to commercial scale-up, with more customer programmes, faster product launches and our chips in the hands of many more developers. Our ambition is clear: to make MintNeuro the semiconductor platform the global neurotechnology industry builds on.”
Founded in 2022 as a spinout from Imperial College London, MintNeuro is developing specialised semiconductor chips for the next generation of neurotechnology. Its chips are designed to help devices connect with the brain and nervous system, supporting the development of new treatments for neurological and mental health conditions.
MintNeuro says its chips can offer better performance than standard components while reducing costs, development risks, and the time needed to bring new devices to market.
The company has already delivered working chips and reached important integration milestones with research and development partners, including Motif Neurotech and Amber Therapeutics.
Earlier this year, MintNeuro also announced a partnership and multi-year commercial chip supply agreement with Motif Neurotech. The agreement supports the development of Motif’s minimally invasive neurostimulator, which is initially being developed to treat treatment-resistant depression.
